About o2h Theraputics EIS Fund
The o2h Therapeutics EIS fund provides investors with the opportunity to invest in the growth potential of UK life science and AI. It has created an integrated model for supporting investee companies. This includes offering these companies a base at its headquarters, recognising that early-stage businesses often require more than funding to succeed.
The minimum subscription is £25,000 and portfolio size is around five-10 companies. The expected exit timescale is within three-seven years.
o2h Theraputics EIS Fund Summary
|Fund Manager:||o2h Ventures|
|Tax Efficiency:||EIS and SEIS|
|Sector Focus:||Biotech, Medtech, and Pharma|
|Target Portfolio Size:||5 - 10 companies|
|Website:||Learn more about o2h Theraputics EIS Fund|
Cambridge-based o2h invests in emerging life-science and technology companies, including those specialising in biotech, digital health and software. The company has an emerging portfolio of seed-stage investments in ‘frontier’ technology companies. Its managing partners are Sunil Shah, who was joint winner of the UK Business Angels Association’s angel of the year award in 2019, and his brother Prashant Shah. To date, they have invested in around 20 biotech companies, mainly in the Cambridge area.
- Website: https://o2h.com
- Address: Hauxton House, Mill SciTech Park, Cambridge, CB22 5H
- Phone: 020 3870 2598
- Email: [email protected]
Are you the fund manager? Email [email protected] with any comments or amends.